Imipenem+Cilastatin/Relebactam
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Complicated Intra-abdominal Infection
Conditions
Complicated Intra-abdominal Infection, Complicated Urinary Tract Infection
Trial Timeline
Oct 4, 2017 → Sep 14, 2018
NCT ID
NCT03293485About Imipenem+Cilastatin/Relebactam
Imipenem+Cilastatin/Relebactam is a phase 3 stage product being developed by Merck for Complicated Intra-abdominal Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT03293485. Target conditions include Complicated Intra-abdominal Infection, Complicated Urinary Tract Infection.
What happened to similar drugs?
4 of 20 similar drugs in Complicated Intra-abdominal Infection were approved
Approved (4) Terminated (3) Active (15)
🔄HRS-8427 + Imipenem and Cilastatin Sodium + HRS-8427 placebo + Imipenem and Cilastatin Sodium placeboJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03293485 | Phase 3 | Completed |
Competing Products
20 competing products in Complicated Intra-abdominal Infection